Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3,647.15INR
17 Apr 2015
Change (% chg)

Rs-33.15 (-0.90%)
Prev Close
Rs3,680.30
Open
Rs3,665.40
Day's High
Rs3,700.00
Day's Low
Rs3,620.00
Volume
258,444
Avg. Vol
330,376
52-wk High
Rs3,807.80
52-wk Low
Rs2,246.50

REDY.NS

Chart for REDY.NS

About

Dr.Reddy's Laboratories Ltd is an India-based integrated global pharmaceutical company that provides medicines. The Company derives its revenue from the sale of finished dosage forms, active pharmaceutical ingredients and intermediates, development and manufacturing services provided to pharmaceutical and biotechnology... (more)

Overall

Beta: 0.26
Market Cap(Mil.): Rs621,405.69
Shares Outstanding(Mil.): 170.38
Dividend: 18.00
Yield (%): 0.49

Financials

  REDY.NS Industry Sector
P/E (TTM): 177.32 40.59 41.17
EPS (TTM): 20.57 -- --
ROI: -- 16.74 16.08
ROE: -- 17.27 16.92
Search Stocks

BUZZ-India's Dr.Reddy's up on hopes of US FDA resolution of Srikakulam plant

** The generic drug maker remains confident of a faster resolution of US FDA observations at the Srikakulam plant - CLSA

31 Mar 2015

BUZZ-India's Dr.Reddy's rises on agreement to market new drug

** Shares of Indian pharmaceutical company Dr.Reddy's Laboratories Ltd gain 1.1 pct

24 Mar 2015

BUZZ-Investors take tactical refuge in Indian pharma ahead of Fed

** Pharmaceutical stocks, traditionally seen as defensives, gain on churning ahead of the U.S. Federal Reserve policy meeting outcome on Wednesday

17 Mar 2015

Dr.Reddy's in talks to buy UCB India business for $135 mln - source

MUMBAI, March 10 - Indian drugmaker Dr.Reddy's Laboratories Ltd is in talks to acquire the Indian operations of Belgian pharmaceutical company UCB SA for about $135 million, said a person with direct knowledge of the matter.

10 Mar 2015

Indian shares continue to fall ahead of RBI review

MUMBAI, Feb 2 - Indian shares fell on Monday, continuing their retreat from record highs hit last week as blue-chips including Dr.Reddy's Laboratories extended falls after disappointing earnings, while caution prevailed a day before the central bank's policy review.

02 Feb 2015

BUZZ-India's Dr Reddy's falls; Credit Suisse cuts to "neutral"

** Delay in monetisation of key drugs such as Nexium and Copaxone, which implies low-teen FY16 EPS growth - Credit Suisse

30 Jan 2015

BUZZ-India's Dr.Reddy's falls; Health Canada quarantines products from Srikakulam plant

** Dr.Reddy's Laboratories shares fall 1.2 pct ** Canadian importers agree to quarantine products from Dr.Reddy's Srikakulam plant and Ipca Laboratories' Pithampur facility, Health Canada says (http://bit.ly/1HyUTK4) ** Quarantine request due to data integrity concerns, Canadian drug regulator adds ** Continued concerns that sales in Russia may be impacted due to brewing financial crisis in the region also weigh (Reuters Messaging: abhishek.vishnoi.thomsonreuters.com@reuters.net)

24 Dec 2014

Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

Shares of India's Dr Reddy's Laboratories gain 0.9 percent.

05 Nov 2014

MARKET EYE-India's Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

* Shares of India's Dr Reddy's Laboratories gain 0.9 percent. * Morgan Stanley upgrades the stock to "overweight" from "equal-weight"; raises price target to 3,875 rupees from 3,049 rupees. * Says drugmaker's U.S. pipeline outlook has strengthened and valuations appears to be reasonable. * "We expect a better outlook for FY16 and FY17 as underlined by improving India, and US businesses," it said. (indulal.p@thomsonreuters.com/indulal.p.thomsonreuters.com@reut ers.net)

05 Nov 2014

Earnings vs. Estimates

Search Stocks